drugset / Trial / NCT00606593
Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia
RandomizedCrossoverQuadruple-blindTreatment
Summary
A 2-night polysomnography / 5-way cross-over study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in elderly subjects with primary insomnia.
Timeline
- Start
- 2007-12
- Primary completion
- 2008-04
- Completion
- 2008-05
Outcome
Met primary endpoint
registry Placebo vs ACT-078573 25 mg; p = 0.0018; Least square means treatment effect -10.4 (95% CI -17.0 to -3.9) NCT00606593 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | almorexant | Small molecule | 25 mg | Oral |
| Subject | almorexant | Small molecule | 50 mg | Oral |
| Subject | almorexant | Small molecule | 100 mg | Oral |
| Subject | almorexant | Small molecule | 200 mg | Oral |